FDA Approved: EVISTA — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

FDA approved a supplemental application for Evista (raloxifene hydrochloride) filed by Eli Lilly, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Breast Cancer
• Osteoporosis

Drugs mentioned

• Evista (raloxifene)

Snippet

SUPPL AP for EVISTA (RALOXIFENE HYDROCHLORIDE)